Strategy

5/7/2012 – “Insight: Training immune system to fight cancer comes of age” by Bill Berkrot of Reuters

3/2/2012 – “Biotech Stock Mailbag: Cyclacel Fallout, the Skinny on Vivus, Celldex’s Crash” by Adam Feuerstein of TheStreet.com

2/27/2012 – “Dendreon Shares Drop on Slowing Sales of Cancer Vaccine Provenge” by Brett Chase of Minyanville

1/26/2012 – “Amgen, Celgene, Roche Deals Signal M&A Frenzy for Drug Companies” by Brett Chase of Minyanville

1/5/2012 – “Dendreon reports spike in Provenge sales; shares soar” by Bill Berkrot of Reuters

10/11/2011 – “Nobel prize-winning science should incubate deals” by David Holley of The Deal

10/7/2011 – “Zytiga creeps up on Provenge prostate-cancer drug” by Ransdell Pierson of Reuters

8/23/2011 – “What’s a Cancer Drug Worth?” by Brett Chase of Minyanville

8/22/2011 – “With Dendreon Humbled, Lessons Learned For Cancer Vaccine Makers” by Emily Hayes of The Pink Sheet